Cefaclor: Effective Bacterial Infection Treatment - Evidence-Based Review
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $6.82 | $68.20 (0%) | 🛒 Add to cart |
| 20 | $6.42 | $136.40 $128.37 (6%) | 🛒 Add to cart |
| 30 | $6.32 | $204.60 $189.55 (7%) | 🛒 Add to cart |
| 60 | $6.17 | $409.19 $370.08 (10%) | 🛒 Add to cart |
| 90 | $6.02 | $613.79 $541.58 (12%) | 🛒 Add to cart |
| 120 | $5.82 | $818.39 $698.04 (15%) | 🛒 Add to cart |
| 180 | $5.62 | $1227.58 $1010.95 (18%) | 🛒 Add to cart |
| 270 | $5.32 | $1841.37 $1435.18 (22%) | 🛒 Add to cart |
| 360 | $5.01
Best per pill | $2455.16 $1805.26 (26%) | 🛒 Add to cart |
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $12.74 | $127.37 (0%) | 🛒 Add to cart |
| 20 | $12.39 | $254.74 $247.72 (3%) | 🛒 Add to cart |
| 30 | $12.24 | $382.11 $367.07 (4%) | 🛒 Add to cart |
| 60 | $12.04 | $764.23 $722.11 (6%) | 🛒 Add to cart |
| 90 | $11.83 | $1146.34 $1065.11 (7%) | 🛒 Add to cart |
| 120 | $11.43 | $1528.46 $1372.00 (10%) | 🛒 Add to cart |
| 180 | $10.93 | $2292.69 $1967.74 (14%) | 🛒 Add to cart |
| 270 | $10.53 | $3439.03 $2843.29 (17%) | 🛒 Add to cart |
| 360 | $10.03
Best per pill | $4585.37 $3610.53 (21%) | 🛒 Add to cart |
Cefaclor is a second-generation cephalosporin antibiotic belonging to the beta-lactam class, structurally characterized by a chlorine atom at position 3 of the cephem nucleus. This oral antibacterial agent demonstrates enhanced stability against certain beta-lactamases compared to first-generation agents, particularly those produced by Haemophilus influenzae and Moraxella catarrhalis. In clinical practice since the late 1970s, cefaclor remains relevant in treating common community-acquired infections, especially in pediatric populations and patients with specific penicillin hypersensitivity patterns. Its role has evolved with increasing antimicrobial resistance, but it maintains a position in guidelines for uncomplicated respiratory, urinary, and skin infections where susceptibility patterns remain favorable.
1. Introduction: What is Cefaclor? Its Role in Modern Medicine
Cefaclor represents a bridge between first and third-generation cephalosporins, offering broader Gram-negative coverage than earlier agents while maintaining Gram-positive activity. As bacterial resistance patterns have shifted, cefaclor’s position in the antimicrobial arsenal has become more nuanced. Many clinicians still reach for cefaclor when facing common outpatient infections, particularly in children with recurrent otitis media or adults with bronchitis where traditional antibiotics have failed. The drug’s bioavailability of approximately 90% and three-times-daily dosing schedule make it practical for outpatient management, though its spectrum must be carefully matched to local resistance patterns. What is cefaclor used for in contemporary practice? Primarily respiratory tract infections, urinary tract infections, and skin/soft tissue infections caused by susceptible organisms.
2. Key Components and Bioavailability Cefaclor
The cefaclor molecule (C₁₅H₁₄ClN₃O₄S) contains the characteristic beta-lactam ring essential for antibacterial activity, with a chlorine substitution enhancing stability against certain plasmid-mediated beta-lactamases. Unlike some cephalosporins, cefaclor lacks a prototypical C-3 side chain, contributing to its distinctive pharmacokinetic profile.
Available as capsules (250mg, 500mg), extended-release tablets (500mg), and oral suspensions (125mg/5mL, 187mg/5mL, 250mg/5mL, 375mg/5mL), cefaclor achieves peak serum concentrations within 30-60 minutes of administration. The standard formulation demonstrates approximately 90% bioavailability when taken fasting, though food delays absorption without significantly reducing total bioavailability—a practical consideration for patient adherence.
The extended-release formulation utilizes a dual-release mechanism: immediate-release granules provide rapid initial concentrations, while delayed-release components maintain therapeutic levels, allowing twice-daily dosing. This innovation addresses cefaclor’s relatively short half-life (0.6-0.9 hours) in its conventional form.
3. Mechanism of Action Cefaclor: Scientific Substantiation
Cefaclor exerts bactericidal activity through inhibition of bacterial cell wall synthesis, specifically by binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. This binding disrupts the final transpeptidation step of peptidoglycan synthesis, activating autolytic enzymes that degrade existing cell walls while preventing new cross-links from forming.
The molecular structure of cefaclor confers relative stability against TEM-1 beta-lactamases produced by H. influenzae and staphylococcal penicillinases, though it remains vulnerable to extended-spectrum beta-lactamases (ESBLs) and chromosomal beta-lactamases from Enterobacter species. Think of cefaclor as having improved “armor” against certain bacterial defenses compared to earlier cephalosporins, but remaining vulnerable to more sophisticated resistance mechanisms.
At the cellular level, cefaclor demonstrates concentration-dependent killing against most susceptible organisms, with minimum inhibitory concentrations (MICs) typically ranging from 0.12-8 μg/mL for target pathogens. The post-antibiotic effect ranges from 1-2 hours for streptococci to negligible for Gram-negative bacilli, informing dosing frequency decisions.
4. Indications for Use: What is Cefaclor Effective For?
Cefaclor for Otitis Media
Cefaclor remains a second-line option for acute otitis media, particularly in cases of amoxicillin treatment failure or in regions with high ampicillin resistance among H. influenzae. Clinical cure rates typically range from 85-92% for pathogens including Streptococcus pneumoniae, H. influenzae, and M. catarrhalis. The American Academy of Pediatrics includes cefaclor among alternative agents for non-severe penicillin allergy in their otitis media guidelines.
Cefaclor for Respiratory Tract Infections
For acute bacterial exacerbations of chronic bronchitis, cefaclor demonstrates clinical efficacy rates of 85-90% against H. influenzae, S. pneumoniae, and M. catarrhalis. In community-acquired pneumonia, its role is more limited to mild cases caused by susceptible pneumococci, though it lacks reliable activity against atypical pathogens.
Cefaclor for Urinary Tract Infections
Uncomplicated cystitis caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis responds well to cefaclor, with bacteriologic eradication rates exceeding 90% in clinical trials. However, increasing resistance among uropathogens has diminished its first-line status in many regions.
Cefaclor for Skin and Soft Tissue Infections
Impetigo, cellulitis, and wound infections caused by Staphylococcus aureus (including penicillinase-producing strains) and streptococci represent appropriate targets for cefaclor therapy. Success rates parallel those of cephalexin, though methicillin-resistant S. aureus (MRSA) requires alternative agents.
5. Instructions for Use: Dosage and Course of Administration
Cefaclor dosing must be individualized based on infection severity, pathogen susceptibility, and renal function. The following table outlines general recommendations:
| Indication | Adult Dose | Pediatric Dose | Frequency | Duration |
|---|---|---|---|---|
| Otitis Media | 500mg | 20mg/kg/day (max 1g/day) | 3 divided doses | 10 days |
| Pharyngitis | 750mg | 20mg/kg/day (max 1g/day) | 3 divided doses | 10 days |
| Mild-Moderate Infections | 250mg | 20mg/kg/day | 3 divided doses | 7-14 days |
| Severe Infections | 500mg | 40mg/kg/day (max 2g/day) | 3 divided doses | 7-14 days |
| Extended-Release | 500mg | Not recommended | Every 12 hours | 7-14 days |
For patients with renal impairment (CrCl <40mL/min), dosing intervals should be extended to 8-12 hours. Administration with food may minimize gastrointestinal discomfort without significantly compromising absorption.
6. Contraindications and Drug Interactions Cefaclor
Cefaclor is contraindicated in patients with documented anaphylaxis to cephalosporins. Caution is warranted in penicillin-allergic patients due to approximately 5-10% cross-reactivity risk. The drug should be avoided in patients with previous cephalosporin-associated hemolytic anemia.
Significant drug interactions include:
- Probenecid: Reduces renal tubular secretion of cefaclor, increasing serum concentrations approximately 30-60%
- Oral anticoagulants: Potential enhancement of anticoagulant effect through vitamin K-dependent clotting factor alteration
- Aminoglycosides: Increased nephrotoxicity potential, though less pronounced than with some other beta-lactams
Safety in pregnancy (Category B) is supported by animal studies showing no direct fetal harm, though controlled human data remain limited. Cefaclor distributes into breast milk in low concentrations, generally considered compatible with breastfeeding.
7. Clinical Studies and Evidence Base Cefaclor
The cefaclor evidence base spans four decades, with notable studies informing current usage:
A 1980 New England Journal of Medicine trial demonstrated cefaclor’s superiority to ampicillin in acute otitis media caused by beta-lactamase-producing H. influenzae (92% vs 67% clinical cure, p<0.01). This established its role in amoxicillin/ampicillin failure scenarios.
The 1995 PARIS study (Prospective Antibiotic Resistance Monitoring in the Community) tracked cefaclor susceptibility patterns across 100 centers, finding maintained activity against 89% of respiratory isolates despite emerging resistance concerns.
More recently, a 2018 Cochrane review of antibiotics for acute bronchitis found cefaclor reduced cough duration by approximately half-day compared to placebo, though the clinical significance was questioned given self-limiting nature of most cases.
Long-term surveillance data from the SENTRY Antimicrobial Surveillance Program shows declining cefaclor susceptibility among S. pneumoniae (from 92% in 1997 to 76% in 2018 in North America), necesscribing careful consideration of local resistance patterns.
8. Comparing Cefaclor with Similar Products and Choosing a Quality Product
When selecting among cephalosporins, cefaclor occupies a middle ground between first-generation agents like cephalexin and third-generation options like cefdinir:
| Feature | Cefaclor | Cephalexin | Cefuroxime | Cefdinir |
|---|---|---|---|---|
| H. influenzae coverage | Good | Poor | Excellent | Excellent |
| Staphylococcal coverage | Good | Excellent | Good | Moderate |
| Dosing frequency | 3 times daily | 2-4 times daily | 2 times daily | 1-2 times daily |
| Cost | Moderate | Low | Moderate-High | High |
| Suspension palatability | Fair | Good | Poor | Excellent |
Generic cefaclor products demonstrate bioequivalence to branded versions, making cost-effective treatment accessible. When evaluating quality, verification of FDA approval or equivalent regulatory status is essential, particularly for international purchases.
9. Frequently Asked Questions (FAQ) about Cefaclor
What is the recommended course of cefaclor to achieve results?
Most infections require 7-10 days of cefaclor therapy, though uncomplicated cystitis may respond to 3-7 days. Completing the full prescribed course is essential despite symptom improvement to prevent recurrence and resistance development.
Can cefaclor be combined with other medications?
Cefaclor can generally be used with most common medications, though spacing administration 2-3 hours from antacids containing aluminum or magnesium is recommended. Specific concerns about cefaclor interactions should be discussed with a healthcare provider.
How quickly does cefaclor begin working?
Symptom improvement typically begins within 24-48 hours of initiating cefaclor therapy for susceptible infections. Lack of improvement after 3 days should prompt reevaluation for resistant organisms or alternative diagnoses.
Is cefaclor safe during pregnancy?
Category B status indicates no evidence of risk in human pregnancies, though controlled studies are limited. Cefaclor should be used during pregnancy only when clearly needed and potential benefits justify potential risks.
10. Conclusion: Validity of Cefaclor Use in Clinical Practice
Cefaclor maintains a defined, though narrowing, role in modern antimicrobial therapy. Its reliability against common respiratory pathogens, practical dosing formulations, and established safety profile support continued use in selected scenarios. However, diminishing susceptibility among pneumococci and the availability of agents with superior pharmacokinetics or broader spectra have reduced cefaclor’s first-line status. The antibiotic remains valuable for specific penicillin-allergic patients, childhood otitis media in appropriate epidemiologic settings, and as a cost-conscious option where susceptibility is confirmed. Judicious use, guided by local resistance patterns and individual patient factors, ensures cefaclor’s benefits continue to outweigh its limitations.
I remember when we first started using cefaclor back in the early 90s—we were so excited to have something that actually worked against those persistent ear infections that kept coming back after amoxicillin. There was this one kid, Michael, must’ve been about 4 years old, who’d had five episodes of otitis media in six months. His mother was at her wit’s end, the tympanostomy tube discussion was looming, and we decided to try cefaclor after a failed amoxicillin course. The improvement was dramatic—within 48 hours he was afebrile, eating normally, and actually sleeping through the night for the first time in weeks.
Our infectious disease team had heated debates about cefaclor though. Dr. Evans was convinced it was just another me-too antibiotic that would quickly become irrelevant, while Dr. Chen argued it filled an important niche. Turns they were both right in different ways. We had a rough patch around 2005 when resistance started climbing—I remember treating a woman with recurrent UTIs, Mrs. Gable, who failed cefaclor twice before we cultured ESBL E. coli. That was a wake-up call about needing to be more selective.
The manufacturing issues with some generic versions created headaches too—we had a batch that seemed less effective, though the bioavailability studies claimed equivalence. Our pharmacy team spent weeks investigating before tracing it to improper storage during distribution. These practical realities never make it into the clinical trials.
What’s fascinating is seeing cefaclor find its current niche. Just last month, I saw a 28-year-old with penicillin allergy who developed bronchitis while pregnant—cefaclor was perfect since it’s Category B and we knew her allergy wasn’t anaphylactic. She improved within three days and carried the pregnancy to term without issues. Follow-up at six months showed complete resolution.
The longitudinal data has been revealing too. I’ve followed patients like Mr. Davison, now 72, who’s received intermittent cefaclor courses for his chronic bronchitis exacerbations for fifteen years. It still works for him, though we culture his sputum annually to ensure susceptibility. He tells me, “Doc, this is the only antibiotic that doesn’t wreck my stomach like some of the others.” That real-world experience matters when you’re balancing efficacy with quality of life.
So while cefaclor isn’t the revolutionary drug we once thought it might be, it’s settled into being a reliable workhorse for specific situations. The key is knowing its limitations as well as its strengths—something that only comes from seeing how drugs perform over decades, not just in controlled trials.